{"id":"W4378650540","doi":"10.1016/j.eururo.2023.05.011","title":"Checkpoint Inhibitors in Urothelial Carcinoma—Future Directions and Biomarker Selection","year":2023,"lang":"en","type":"review","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; U.S. Department of Veterans Affairs","keywords":"Medicine; Metastatic Urothelial Carcinoma; Nivolumab; Cystectomy; Oncology; Internal medicine; Pembrolizumab; Bladder cancer; Clinical endpoint; Clinical trial; Cancer; Immunotherapy; Urothelial carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003108397,0.0004180525,0.001081987,0.0005823057,0.00008123869,0.00001855665,0.00008392441,0.0002564261,0.00008402891],"category_scores_gemma":[0.00006427013,0.0003356873,0.0002719381,0.0006466196,0.00009282678,0.0000319176,0.00009773731,0.0006153089,0.0004683888],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001456916,"about_ca_system_score_gemma":0.0002181814,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001167666,"about_ca_topic_score_gemma":0.0001199732,"domain_scores_codex":[0.9976878,0.0006048612,0.000576449,0.0006438894,0.0001250078,0.000361953],"domain_scores_gemma":[0.9993364,0.00007515541,0.0001556188,0.0002545781,0.00003249524,0.0001457761],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009829965,0.0001315479,0.001275796,0.002802107,0.0003244991,0.0006614899,0.000202004,1.153951e-7,0.000006732306,0.00001628241,0.002270385,0.9922107],"study_design_scores_gemma":[0.0009628057,0.000373339,0.008995311,0.0006249417,0.0009306304,0.0007940284,0.00001027329,0.000002361921,0.000001140313,0.000007785045,0.9870754,0.0002219939],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003415096,0.9873313,0.000002846028,0.0002835484,0.001224103,0.0009818402,0.00004675952,0.0001980767,0.009589979],"genre_scores_gemma":[0.0007047107,0.9949835,0.00002335648,0.0001797562,0.001715844,0.00008782354,0.0001031213,0.0001917767,0.002010109],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9919887,"threshold_uncertainty_score":0.9999095,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04715193843860762,"score_gpt":0.3220179099081214,"score_spread":0.2748659714695138,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}